Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted Treatment for Cannabis Use Disorder
NCT06660381Phase 1Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Nov 2024
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in cannabis use disorder (CUD), sponsored by Johns Hopkins University. Primary endpoints: Self-reported cannabis use and Biomarkers of recent cannabis use at 3 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT06660381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660381.